Yahoo Finance
Warren Buffett, Markwayne Mullin Bet On The Same 10 Stocks – Some Might Surprise You
Warren Buffett and Senator Markwayne Mullin — an unlikely pair — share overlapping positions in 10 stocks, revealing where Main Street politics and Wall Street wisdom converge. The crossover holdings span sectors that signal long-term confidence in American industry and financials. For investors, the alignment offers a rare lens into stocks drawing conviction from two very different but influential figures.
Read article →Motley Fool
Is This Stock a Buy on the Dip?
A long-track record of outperforming the market has put this stock back in focus as its price pulls back. Dip-buying opportunities in consistent outperformers are rare, making the timing worth a closer look. For investors with a long-term horizon, the case for stepping in may be stronger than it appears.
Read article →Motley Fool
Uber's Advertising Business May Be Bigger Than Investors Think
Uber's advertising arm is quietly emerging as a significant revenue stream that Wall Street may be undervaluing. Leveraging its massive base of riders and Eats customers, the company is sitting on a goldmine of first-party data and captive audience attention. For investors focused solely on ride-hailing metrics, the ad business could represent a meaningful upside surprise.
Read article →Motley Fool
Why Is SoFi Stock Crashing, and Should You Buy the Dip?
SoFi shares are under pressure as the fintech company battles persistent skepticism from investors unconvinced by its growth trajectory. Despite expanding its product suite and banking charter, the stock continues to face headwinds tied to broader concerns about consumer credit quality and profitability timelines. For contrarian investors, the selloff raises the question of whether current prices represent a genuine opportunity or a value trap.
Read article →Motley Fool
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Cogent Biosciences just received a major vote of confidence as an insider plowed $116 million into the stock, doubling down amid a 360% run-up in share price. The move signals strong internal conviction heading into what appears to be a critical drug launch phase for the precision medicine company. For a rare disease biotech, that kind of insider commitment at elevated prices is a signal the market will find hard to ignore.
Read article →Get this delivered every morning
Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →